异基因造血干细胞移植后复发的慢性淋巴细胞白血病患者接受维奈克拉治疗
该研究报道了意大利53个中心中7例在异基因造血干细胞移植(alloHSCT)后接受维奈克拉治疗的慢性淋巴细胞白血病(CLL)患者。移植后维奈克拉治疗安全,不良事件与临床试验报告无差异,未观察到对移植物抗宿主病(GvHD)病程有有意义的影响;5/7例患者获得临床缓解,其中2例达到不可检测的微小残留病。
要点
- 移植后维奈克拉治疗安全,不良事件与临床试验报告无差异。
- 7例中4例原有慢性GvHD在维奈克拉开始后无加重,仅1例在治疗期间发生GvHD并按标准临床实践处理。
- 5/7例患者对维奈克拉有临床缓解,其中2例达到不可检测的微小残留病。
核心结论
- 在7例经重度预处理的高危CLL患者中,既往alloHSCT未影响维奈克拉治疗的可行性,未出现意外毒性,且未加重GvHD。
- 据作者所知,这是alloHSCT后接受维奈克拉治疗的CLL患者的最大报道系列。
研究设计与样本
- 回顾性报道意大利53个中心中7例在alloHSCT后接受维奈克拉治疗的CLL患者的数据。
- 这些患者在2006年至2021年间接受alloHSCT,移植前均接受过化学免疫治疗(7/7),5/7例接受过伊布替尼,1/7例接受过艾德拉尼。
- 7例中3例在alloHSCT前已接受过基于维奈克拉的治疗。
主要发现
- 移植后维奈克拉治疗安全,不良事件与临床试验报告无差异。
- 7例中4例原有慢性GvHD在维奈克拉开始后无加重,仅1例在维奈克拉治疗期间发生GvHD并按标准临床实践处理。
- 7例中5例对维奈克拉有临床缓解,其中2例达到不可检测的微小残留病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains an option for young and fit chronic lymphocytic leukaemia (CLL) patients with high-risk disease features. However, allotransplanted patients are generally excluded from clinical trials, making data regarding the use of venetoclax after alloHSCT extremely rare. We report data from 7 CLL patients who received venetoclax after alloHSCT among 53 Italian centers. These patients underwent alloHSCT between 2006 and 2021 after failing chemoimmunotherapy (7/7), ibrutinib (5/7) and/or idelalisib (1/7). Of note, 3/7 patients had already received venetoclax-based therapy before alloHSCT. Post-allo HSCT venetoclax treatment resulted safe, with adverse events not different from what reported in clinical trials. Importantly, no meaningful impact on graft versus host disease (GvHD) course was observed: 4/7 patients with pre-existing chronic GvHD had no exacerbation after venetoclax start, and only one patient developed GvHD during venetoclax therapy, that was managed as per standard clinical practice. Concerning efficacy, 5/7 patients presented a clinical response to venetoclax, with two patients achieving an undetectable minimal residual disease. To our knowledge, this is the largest reported series of CLL patients treated with venetoclax after alloHSCT. In these heavily pretreated and high-risk patients, previous alloHSCT did not compromise the feasibility of venetoclax therapy, that lacked unexpected toxicities and did not exacerbate GvHD.
引用
- Perutelli F, Boccellato E, Montalbano MC, et al. Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2025. PMID: 39777647. doi:10.1111/bjh.19976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。